Can-Fite BioPharma shareholders approve two proposals

Can-Fite BioPharma Ltd. reported that shareholders approved both proposals presented at its Special General Meeting on November 10, 2025.

Accepted by SEC EDGAR 11/10/2025 - 04:15 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd. reported that shareholders approved both proposals presented at its Special General Meeting on November 10, 2025. The proposals were described in the company’s Notice and Proxy Statement dated October 3, 2025, which was furnished as Exhibit 99.1 to a prior Form 6-K on October 3, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CANF announce in this Form 6-K?

Shareholders approved each of the two proposals presented at the Special General Meeting on November 10, 2025.

How many proposals were approved by Can-Fite shareholders?

Two proposals were approved.

When did the Special General Meeting take place for CANF?

The meeting took place on November 10, 2025.

Where were the approved proposals described?

In the Notice and Proxy Statement dated October 3, 2025, furnished as Exhibit 99.1 to a Form 6-K on October 3, 2025.

Who signed the report for Can-Fite?

Motti Farbstein signed the report as Chief Executive Officer and Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of November 2025

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On November 10, 2025, a Special General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the “Company”) approved each of the two proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company’s Notice and Proxy Statement with respect to the Company’s Special General Meeting of Shareholders, dated October 3, 2025, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on October 3, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Can-Fite BioPharma Ltd.

Date: November 10, 2025	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

Source: View Original Filing on SEC EDGAR